Spanish Health Ministry to Fund Generic Version of "Champix"

Regulations by 2FIRSTS.ai
May.30.2024
Spanish Health Ministry to Fund Generic Version of "Champix"
Spain's Health Ministry to fund generic version of "Champix" from June, after original version pulled due to impurities.

According to El Mundo on May 29th, the Spanish Ministry of Health will start funding generic versions of "Champix" from June, a drug that was previously removed from the market due to impurities found in the production process of its main component, Varenicline.

 

Susana Verdejo, director of the Tobacco Prevention and Control Department at the Spanish Ministry of Health, revealed during a World No Tobacco Day meeting on Wednesday (May 29) that the active ingredient varenicline in the pharmaceutical giant Pfizer's drug "Champix" was ordered to be removed from shelves in 2021 by the Spanish Agency of Medicines and Medical Devices (AEMPS) due to the presence of carcinogenic nitrosamine impurities above permitted levels during the manufacturing process. It is expected that in June, the version of the drug produced by the designated manufacturer Normon will be available for sale in Spanish pharmacies.

 

In Spain, two smoking cessation medications, "Todacitán" and "Recigarum," have received funding. Therefore, there are currently three smoking cessation medications available in Spain.

 

We welcome news tips, article submissions, interview requests, or comments on this piece.

Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn


Notice

1.  This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.

2.  The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.

3.  This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.

4.  Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.

 

Copyright

 

This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.

For copyright-related inquiries, please contact: info@2firsts.com

 

AI Assistance Disclaimer

 

This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.

We welcome any corrections or feedback. Please contact us at: info@2firsts.com

Scandinavian Tobacco Group Reports Q3 2025 Results and Narrows Full-Year Guidance
Scandinavian Tobacco Group Reports Q3 2025 Results and Narrows Full-Year Guidance
Scandinavian Tobacco Group (STG) reported net sales of DKK 2.4 billion for Q3 2025, in line with last year. EBITDA before special items reached DKK 519 million with a 22.0% margin. Handmade Cigars and Next Generation Products saw organic growth, while Machine-Rolled Cigars and Smoking Tobacco declined. The company narrowed its full-year guidance.
Nov.12 by 2FIRSTS.ai
Mexico’s Congress Prepares Total Ban on Vapes and E-Cigarettes
Mexico’s Congress Prepares Total Ban on Vapes and E-Cigarettes
Mexico’s Chamber of Deputies is preparing to vote on several major bills before the end of the legislative session, including a full ban on vapes and e-cigarettes. The proposed reform to the General Health Law would prohibit the manufacturing, sale, import, and export of these products, imposing penalties of up to eight years in prison and fines exceeding 200,000 pesos (approximately USD 11,000). L
Dec.09 by 2FIRSTS.ai
Illegal Vape Sellers in the Netherlands Could Be Fined Up to €4,040
Illegal Vape Sellers in the Netherlands Could Be Fined Up to €4,040
The outgoing Dutch government plans to raise fines for illegal sales of vapes and cigarettes, with first-time offenders facing a €2,040 penalty. The new fines, up to €4,040 for large companies, are expected to take effect on July 1, 2026, pending parliamentary approval.
Nov.10 by 2FIRSTS.ai
£600,000 of Illegal Goods Seized in West Yorkshire Raids Targeting Vape and Tobacco Laundering
£600,000 of Illegal Goods Seized in West Yorkshire Raids Targeting Vape and Tobacco Laundering
Nearly £600,000 worth of illegal goods were seized in coordinated raids across West Yorkshire as part of Operation Machinize, a nationwide crackdown targeting cash-intensive businesses suspected of laundering money through mini-markets, vape shops, and barbershops.
Nov.12 by 2FIRSTS.ai
IMiracle  Announces 2025 R&D Progress with Over 2,200 Patent Applications Worldwide
IMiracle Announces 2025 R&D Progress with Over 2,200 Patent Applications Worldwide
IMiracle announces significant R&D progress in 2025, with over 2,200 patent applications globally and 900 authorized patents.
Dec.18 by 2FIRSTS.ai
Altria Q3 2025 Earnings Report: Net Revenue of $6.072 Billion and Launch of on!PLUS in the U.S.
Altria Q3 2025 Earnings Report: Net Revenue of $6.072 Billion and Launch of on!PLUS in the U.S.
Altria reported Q3 2025 net revenue of $6.072 billion, a 3.0% year-on-year decline. Adjusted EPS increased 3.6% to $1.45. The company expanded its share repurchase program to $2 billion and launched the on!PLUS nicotine pouch in Florida, North Carolina, and Texas.
Oct.31 by 2FIRSTS.ai